012790 — Sinil Pharmaceutical Co Income Statement
0.000.00%
- KR₩88bn
- KR₩62bn
- KR₩89bn
- 82
- 82
- 33
- 77
Annual income statement for Sinil Pharmaceutical Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 60,648 | 61,438 | 61,754 | 80,007 | 89,135 |
Cost of Revenue | |||||
Gross Profit | 24,875 | 24,204 | 24,441 | 35,645 | 37,570 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 51,248 | 54,519 | 53,758 | 66,443 | 75,151 |
Operating Profit | 9,400 | 6,919 | 7,996 | 13,564 | 13,984 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 8,345 | 8,162 | 8,341 | 14,645 | 14,953 |
Provision for Income Taxes | |||||
Net Income After Taxes | 7,257 | 7,544 | 6,679 | 12,157 | 13,641 |
Net Income Before Extraordinary Items | |||||
Net Income | 7,257 | 7,544 | 6,679 | 12,157 | 13,641 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 7,257 | 7,544 | 6,679 | 12,157 | 13,641 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 644 | 642 | 592 | 1,083 | 1,231 |
Dividends per Share |